US equities |
MU $938.01 ▼-5.16% META $766.30 ▲+3.14% NVDA $227.39 ▲+0.47% SNDK $1,448.32 ▼-2.62% MSFT $545.57 ▲+0.82% AAPL $342.29 ▲+0.39% SPCX $156.62 ▼-4.16% AMD $598.29 ▲+0.68%
FinancialContent

Nkarta, Inc. - Common Stock (NQ:NKTX)

2.105 -0.065 (-3.00%)
Delayed Quote Updated: 3:09 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nkarta, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Nkarta to Participate in September Investor Conferences
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
From Cyllene Therapeutics
Via GlobeNewswire
News headline image
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
From Nkarta, Inc.
Via GlobeNewswire
News headline image
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
From Equity Insider
Via GlobeNewswire
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
From Biotech Insider
Via GlobeNewswire
News headline image
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Participate in Needham Virtual Healthcare Conference
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Participate in March Investor Conferences
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Participate in Evercore Healthcare Conference
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Participate in November Investor Conferences
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2 Next >